2020
Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin
Hema-Ouangraoua S, Zongo I, Kabore N, Frédéric N, Yerbanga R, Tinto H, Compaore Y, Kuepfer I, Chandramohan D, Greenwood B, Ouedraogo J. Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin. American Journal Of Tropical Medicine And Hygiene 2020, 103: 679-683. PMID: 32524945, PMCID: PMC7410481, DOI: 10.4269/ajtmh.19-0944.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoCarrier StateChemopreventionChild, PreschoolDrug CombinationsDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansInfantMalariaMaleMass Drug AdministrationNasopharynxPneumococcal InfectionsPneumococcal VaccinesPyrimethamineSeasonsSerogroupStreptococcus pneumoniaeSulfadoxineConceptsSeasonal malaria chemopreventionMass drug administrationEmergence of resistancePneumococcal serotypesDrug AdministrationStreptococcus pneumoniaeDistribution of serotypesMalaria chemopreventionNasopharyngeal isolatesMass administrationCarriage studiesAzithromycinQuellung techniqueSwift appearanceSpecific serotypesSingle serotypeAdministrationAntibiotic resistanceSerotype profileSerotypesDifferent serotypesMultiplex assayPneumoniaePCR techniqueIsolates
2019
Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae
Hema‐Ouangraoua S, Maiga A, Cairns M, Zongo I, Frédéric N, Yerbanga R, Tamboura B, Badji H, Gore‐Langton G, Kuepfer I, Tinto H, Sagara I, Dicko A, Sow S, Chandrahoman D, Greenwood B, Ouedraogo J. Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae. Tropical Medicine And International Health 2019, 24: 1442-1454. PMID: 31655020, PMCID: PMC7687265, DOI: 10.1111/tmi.13321.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria chemopreventionNasopharyngeal swabsStreptococcus pneumoniaeAnnual malaria transmission seasonsMalaria transmission seasonResistance of pneumococciMalian childrenHospital admissionAzithromycin 1Nasal isolatesAntimalarial combinationLast administrationPneumococcal isolatesTransmission seasonDrug AdministrationAzithromycinChemopreventionResistant isolatesAntimalarialsAntimicrobial resistancePlaceboBurkina FasoChildren
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infection